Loading company…
Sydney-based Minomic develops MiCheck Prostate, a blood test that supports prostate biopsy decisions and cancer risk assessment.
Founded in 2007 in Sydney, Australia, Minomic International Ltd develops and commercializes diagnostic tests for prostate cancer. Its flagship MiCheck Prostate is a biomarker blood test for men being considered for a prostate biopsy, sold to urologists and healthcare providers in the US and Australia. The company has completed three investment deals, most recently raising AUD 9.2 million in December 2016 from undisclosed investors, and CEO Brad Walsh leads it. It is at the Series A stage.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in